Tempus AI, Inc. (TEM) Enterprise Value (EV): $8.87B
The enterprise value (EV) for Tempus AI, Inc. (TEM) is $8.87B as of Friday, June 12, 2026.
TEM Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$8.87B
TEM Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | $8.87B |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | $12.95B |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | $9.26B |
| Baxter International Inc. (BAX) | $10.58B | $17.84B |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | $8.34B |
| Align Technology, Inc. (ALGN) | $12.27B | $10.36B |
| Solventum Corporation (SOLV) | $13.72B | $17.95B |
| Hologic, Inc. (HOLX) | $16.97B | $15.94B |
| 23andMe Holding Co. (ME) | $15.31M | $49.27M |
| Moderna, Inc. (MRNA) | $18.71B | $10.79B |
Enterprise Value Calculation
Market Cap
$8.65B
Total Debt
$815.71M
Cash
$604.79M
Enterprise Value
$8.87B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Tempus AI, Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Tempus AI, Inc. (TEM)?
- The enterprise value (EV) for TEM stock is $8.87B.
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky